IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy
- PMID: 35537409
- DOI: 10.1016/j.ccell.2022.04.010
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy
Abstract
Increasing the efficacy of immune checkpoint blockade therapy while mitigating toxicity is one of the major challenges in oncology research. In this issue of Cancer Cell, Hailemichael et al. provide a strong rationale for the combination of IL-6 blockade and dual inhibition of CTLA-4 and PD-1 to overcome this issue.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.L. reports research funding (Roche, BMS), consulting fees (BMS, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre), honoraria (Roche, BMS, Novartis, Amgen, MSD, Pierre Fabre, Pfizer, Incyte), speaker’s bureau membership (Roche, BMS, Novartis, Amgen, MSD), support for attending meetings (BMS, MSD, Novartis, Sanofi, Pierre Fabre), and other interests (Avantis Medical Systems). J.D. reports honoraria (BMS) and research funding (Amgen, MSD).
Comment on
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.Cancer Cell. 2022 May 9;40(5):509-523.e6. doi: 10.1016/j.ccell.2022.04.004. Epub 2022 May 9. Cancer Cell. 2022. PMID: 35537412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous